

JC931 U.S. PTO  
12/10/01

Attorney Docket No.: 4366.220-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## FILING UNDER 37 C.F.R. 1.53(b)

JC580 U.S. PTO  
10/007521  
12/10/01

Box Patent Application  
Commissioner for Patents  
Washington, DC 20231

Sir:

This is a request for filing a patent application under 37 CFR 1.53(b).

INVENTOR(S)		
First Name	Middle Name	Family Name or Surname
1. Martin	1.	1. Schulein
2. Lene	2. Nonboe	2. Andersen
3. Soren	3. Flensted	3. Lassen
4. Markus	4. Sakari	4. Kauppinen
5. Lene		5. Lange
6. Ruby	6. Illum	6. Nielsen
7. Shinobu		7. Takagi
8. Michiko		8. Ihara

  

TITLE OF THE INVENTION		
Novel Endoglucanases		

The following application parts are enclosed:

specification 114 pages  Sequence Listing 71 pages  
 Abstract 1 page  Formal Drawings 8 pages

The filing fee is calculated as follows:

Basic Fee:	\$740.00
Total Claims: $12 - 20 = 0 \times 18 =$	\$0.00
Independent Claims: $3 - 3 = 0 \times 84 =$	\$0.00
Total Fee:	\$740.00

Priority of Danish application no. 0272/95, 0888/95, 0887/95, 0886/95, 0885/95 and 0137/96 filed on March 17, 1995, August 8, 1995, August 8, 1995, August 8, 1995, and February 12, 1996, are claimed under 35 U.S.C. 119(a)-(d). Certified copies were filed in the parent case.

The benefit of U.S. application no. 08/651,136, filed on May 21, 1996, and application no. 09/229,991, filed on January 13, 1999, is claimed under 35 U.S.C. 120.

An application data sheet is enclosed.

The computer-readable form in this application is identical with that filed in application no. 08/651,136, filed May 21, 1996. In accordance with 37 CFR 1.821(e), please use the last filed computer readable form filed in that application as the computer readable form for the instant application. The content of the attached Sequence Listing and of the computer readable form filed in the parent application is the same.

The assignee of the present application is:

Novozymes A/S  
Krogshoejvej 36  
DK-2880 Bagsvaerd  
Denmark

Applicants request that the assignee information be included in the published patent application.

Direct all correspondence to Customer Number 25908:

PATENT TRADEMARK OFFICE



25908

Please charge the required fee, estimated to be \$740, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,



---

Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

Date: December 5, 2001

12/10/01  
JC931 U.S. PTO

12-10-01

PATENT

A  
Seq WPA

Attorney Docket No.: 4366.220-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application  
United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Re: U.S. Patent Application for  
Title: Endoglucanases  
Applicants: Schulein et al.

Sir:

Express Mail Label No. 896275054 US

Date of Deposit: December 5, 2001

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Application Data Sheet
4. Preliminary Amendment
5. Executed Copy of Declaration
7. Information Disclosure Statement
8. Form PTO-1449

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, DC 20231.

Kelley O'Patry

(Name of person mailing paper(s) or fee)

K. O'Patry

(Signature of person mailing paper(s) or fee)

Mailing Address:  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10017  
(212) 867-0123